Literature DB >> 31221475

Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals.

Joanne Bryant1, Jake Rance2, Peter Hull3, Limin Mao4, Carla Treloar5.   

Abstract

Direct-Acting Antiviral (DAA) treatments for hepatitis C have been widely promoted by health promotion professionals and medical clinicians as being 'side-effect free'. In this paper, we draw on data that troubles this approach. We used a mixed method design to collect data from people who inject drugs, and who were DAA treatment naïve, in New South Wales, Australia. We describe knowledge about and perceptions of DAA treatment. We found that concerns about side effects were commonplace - for example, one-third (37%) of participants who had not taken up treatment worried "a lot" about 'side effects' - and that these concerns were underpinned by a general distrust and suspicion of medical institutions and their technologies, including widespread negative associations linked to interferon treatment. In trying to make sense of this, we draw on the concept of counterpublic health and its recognition that the everyday health needs, knowledges and aspirations of subordinated citizens frequently contradict the normative frameworks governing public health interventions. We suggest that failing to engage with concerns about 'side effects' could hinder elimination efforts. Our analysis suggests that addressing the issue of 'side effects' within the 'public' discourse of DAAs will not dampen or damage elimination efforts, as some might fear, but rather it will legitimate the concerns of people who inject, decrease their suspicion of medical interventions, and better support the uptake of DAA treatments.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Counterpublic health; Direct-acting antivirals; Hepatitis C; Side effects

Mesh:

Substances:

Year:  2019        PMID: 31221475     DOI: 10.1016/j.drugpo.2019.06.002

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  10 in total

1.  Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment.

Authors:  Sarah Brothers; Elizabeth DiDomizio; Lisa Nichols; Ralph Brooks; Merceditas Villanueva
Journal:  AIDS Behav       Date:  2022-07-01

2.  Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patient and treatment provider perceptions.

Authors:  David Ortiz-Paredes; Afia Amoako; David Lessard; Kim Engler; Bertrand Lebouché; Marina B Klein
Journal:  Can Liver J       Date:  2022-05-09

3.  Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers.

Authors:  David Ortiz-Paredes; Afia Amoako; David Lessard; Kim Engler; Bertrand Lebouché; Marina B Klein
Journal:  Can Liver J       Date:  2022-02-04

4.  Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study.

Authors:  Bernd Schulte; Christiane S Schmidt; Jakob Manthey; Lisa Strada; Stefan Christensen; Konrad Cimander; Herbert Görne; Pavel Khaykin; Norbert Scherbaum; Stefan Walcher; Stefan Mauss; Ingo Schäfer; Uwe Verthein; Jürgen Rehm; Jens Reimer
Journal:  Open Forum Infect Dis       Date:  2020-08-13       Impact factor: 3.835

Review 5.  Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world.

Authors:  Sarah R Donaldson; Andrew Radley; John F Dillon
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-06-08

6.  Individual and network factors associated with HCV treatment uptake among people who inject drugs.

Authors:  Oluwaseun Falade-Nwulia; Paul Sacamano; Sean D McCormick; Cui Yang; Greg Kirk; David Thomas; Mark Sulkowski; Carl Latkin; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2020-03-02

7.  Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol.

Authors:  Sarah R Donaldson; Andrew Radley; John F Dillon
Journal:  BMJ Open       Date:  2022-02-07       Impact factor: 2.692

8.  Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project.

Authors:  Julia A Silano; Carla Treloar; Kyle Leadbeatter; Sandy Davidson; Justine Doidge
Journal:  Harm Reduct J       Date:  2022-04-21

9.  Hepatitis C cure as a 'gathering': Attending to the social and material relations of hepatitis C treatment.

Authors:  Adrian Farrugia; Renae Fomiatti; Suzanne Fraser; David Moore; Michael Edwards; Elizabeth Birbilis; Carla Treloar
Journal:  Sociol Health Illn       Date:  2022-04-01

10.  People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study.

Authors:  Anna Conway; Carla Treloar; Sione Crawford; Jason Grebely; Alison D Marshall
Journal:  Drug Alcohol Rev       Date:  2022-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.